BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 9738588)

  • 21. 11th Ernst Klenk Lecture. The p53 tumor suppressor gene and product.
    Levine AJ
    Biol Chem Hoppe Seyler; 1993 Apr; 374(4):227-35. PubMed ID: 8329141
    [No Abstract]   [Full Text] [Related]  

  • 22. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
    Müller P; Nenutil R; Vojtĕsek B
    Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cell death machinery governed by the p53 tumor suppressor in response to DNA damage.
    Yoshida K; Miki Y
    Cancer Sci; 2010 Apr; 101(4):831-5. PubMed ID: 20132225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage.
    Camplejohn RS; Perry P; Hodgson SV; Turner G; Williams A; Upton C; MacGeoch C; Mohammed S; Barnes DM
    Br J Cancer; 1995 Sep; 72(3):654-62. PubMed ID: 7669577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications of the p53 tumor-suppressor gene in clinical oncology.
    Chang F; Syrjänen S; Syrjänen K
    J Clin Oncol; 1995 Apr; 13(4):1009-22. PubMed ID: 7707100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The tumor suppressor gene p53 (part one). Structure, function and mechanisms of inactivation].
    Martin A
    Ann Pathol; 1995; 15(3):178-83. PubMed ID: 7639853
    [No Abstract]   [Full Text] [Related]  

  • 27. Normal and malignant growth control by p53.
    Finlay CA
    Cancer Treat Res; 1992; 63():327-44. PubMed ID: 1363365
    [No Abstract]   [Full Text] [Related]  

  • 28. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 and p21waf-1 expression correlates with apoptosis or cell survival in poorly differentiated, but not well-differentiated, retinoblastomas.
    Divan A; Lawry J; Dunsmore IR; Parsons MA; Royds JA
    Cancer Res; 2001 Apr; 61(7):3157-63. PubMed ID: 11306502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tumor suppressor gene p53].
    Tokino T
    Nihon Rinsho; 1996 Apr; 54(4):960-4. PubMed ID: 8920657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P53 and induction of apoptosis as a target for anticancer therapy.
    Neubauer A; Thiede C; Huhn D; Wittig B
    Leukemia; 1996 Jul; 10 Suppl 3():S2-S4. PubMed ID: 8656696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour suppression by p53: the importance of apoptosis and cellular senescence.
    Zuckerman V; Wolyniec K; Sionov RV; Haupt S; Haupt Y
    J Pathol; 2009 Sep; 219(1):3-15. PubMed ID: 19562738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis.
    Hussain SP; Harris CC
    J Nippon Med Sch; 2006 Apr; 73(2):54-64. PubMed ID: 16641528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of p53 activation--spoilt for choice.
    Vousden KH
    J Cell Sci; 2006 Dec; 119(Pt 24):5015-20. PubMed ID: 17158908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53--a natural cancer killer: structural insights and therapeutic concepts.
    Römer L; Klein C; Dehner A; Kessler H; Buchner J
    Angew Chem Int Ed Engl; 2006 Oct; 45(39):6440-60. PubMed ID: 16983711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression and role of p53 in the retina.
    Vuong L; Conley SM; Al-Ubaidi MR
    Invest Ophthalmol Vis Sci; 2012 Mar; 53(3):1362-71. PubMed ID: 22427613
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation and activities of the p53 tumour suppressor protein.
    Bálint E E; Vousden KH
    Br J Cancer; 2001 Dec; 85(12):1813-23. PubMed ID: 11747320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of p53 in cell-cycle control and apoptosis: implications for cancer.
    Leonard CJ; Canman CE; Kastan MB
    Important Adv Oncol; 1995; ():33-42. PubMed ID: 7672812
    [No Abstract]   [Full Text] [Related]  

  • 39. p53 from basic research to clinical applications.
    Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
    Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [P53 mutations, asset or disadvantage for cancer chemotherapy].
    Jacquemin-Sablon A
    Bull Cancer; 1997 Jul; 84(7):741-6. PubMed ID: 9339201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.